Genentech Pulls Tecentriq Indication in Bladder Cancer Two Plus Years After Trial Failure

FDA leaders’ efforts to enact meaningful accelerated approval reform — minus any Congressional support — are beginning to show dividends.
Source: Drug Industry Daily